« Incyte announced that they are working in partnership with the FDA to initiate a phase III clinical trial to evaluate the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with coronavirus disease 2019 (COVID-19) induced cytokine storm. »
Jakafi for Patients with COVID-19: « Incyte... - MPN Voice
Jakafi for Patients with COVID-19
Written by
Manouche
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Not what you're looking for?
You may also like...
Impact of COVID-19 infection in blood cancer patients
JUNE 2, 2020
Impact of COVID-19 infection in blood cancer patients...
CHANGE OF DATE for the webinar for MPN patients relating to government guidance on COVID-19
Leukaemia Care to share the government guidance on COVID-19 and how this relates to MPN patients....
COVID-19 and Ruxolitnib
targetedonc.com/news/phase-iii-trial-planned-for-ruxolitinib-to-treat-covid19related-cytokine-storm.
ASH 2020 | Impact of COVID-19 on MPNs patients
8-)
Steve
ASH 2020 | Impact of COVID-19 on MPNs patients...
Research to investigate how patients with MPN and also CML respond to vaccination against Covid-19
investigate how patients with MPN and also CML respond to vaccination against Covid-19.
They would...
Covid-19 and blood clotting
Blood cancer and Covid 19 Vaccinations
Covid-19 
COVID 19 Facts You may not know
